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for the CFAR Network of Integrated Clinical Systems (CNICS)Abstract
We determined risk of virologic failure (VF) in individuals initiating tenofovir/emtricitabine/efavirenz as single versus multiple tablet
regimens (MTR). We found no significant difference in the risk of VF, though did observe a trend toward more VF and M184V
mutations among persons initiating MTR. Temporal trends in care may have confounded results.
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Integrated Clinical Systems, DHHS = Department of Health and Human Services, FTC = emtricitabine, HIV = human
immunodeficiency virus, HR = hazard ratio, IAS-USA = International Antiviral Society United States of America, MTR =multiple tablet
regimen, STR = single tablet regimen, TFE = tenofovir/emtricitabine (FTC)/efavirenz, US = United States, VF = virologic failure, VL =
viral load.
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11. Introduction
Guidelines from the United States Department of Health and
Human Services (DHHS) and the International Antiviral Society
USA (IAS-USA) recommend treatment with combination antire-
troviral therapy (ART) for all individuals infected with human
immunodeficiency virus (HIV).[1,2] These recommendations have
resulted in a dramatic increase in the number of persons in the
United States (US) eligible for ART treatment compared with
prior guidelines.[3,4] Two concurrent trends have accompanied
the increase in patients eligible for treatment, which have the
potential to increase the overall cost and success of expanded
ART coverage: first, the introduction of fixed-dose combination
or single-tablet regimens (STR) for the treatment of HIV and
second the increase in the number of antiretrovirals (ARVs) that
are now available as generic medications. Existing studies have
shown that ART adherence is essential to themaintenance of viral
suppression and prevents hospitalizations, AIDS, and death.[5–7]
STRs may improve regimen durability[8] and adherence.[9,10] If
clinicians are able to construct potent, durable, and tolerable
regimens using generic medications, the potential for cost savings
exists though this may also lead to more complex regimens that
may impact adherence. We aimed to determine the risk of
virologic failure (VF) in ART-naive individuals starting a
tenofovir/emtricitabine (FTC) /efavirenz (TFE) regimen as either
an STR or multiple tablet regimen (MTR). To our knowledge this
is the first study to compare ART-naive patients starting an STR
to those starting anMTRusing the same component medications.2. Methods
This study was conducted in the Centers for AIDS Research
(CFAR) Network of Integrated Clinical Systems (CNICS) cohort
that contains clinical data on >30,000 HIV-infected patients
Table 1
Baseline characteristics.
MTR (n=404) STR (n=1854)
Mean age (SD) 38.9 (9.8) 38.4 (10.4)
Male sex, % 349 (86) 1629 (88)
Race/ethnicity, %
Black 150 (37) 589 (32)
White 208 (52) 968 (52)
Other 46 (11) 297 (16)
HIV transmission risk factor
MSM 234 (58) 1197 (65)
IDU 54 (13) 206 (11)
Other 116 (29) 451 (24)
Mean CD4 [cells/mL] (SD) 206 (148) 296 (198)
Mean log HIV VL [copies/mL] (SD) 5.0 (0.7) 4.7 (0.7)
IDU= injection drug user, MSM=men who have sex with men, MTR=multitablet regimen, SD=
standard deviation, STR= single-tablet regimen.
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(Case Western Reserve University, Harvard Fenway, Johns
Hopkins University, University of Alabama Birmingham,
University of California San Diego, University of California
San Francisco, University of North Carolina, and University of
Washington) across the United States.[11] The CNICS repository
systematically integrates demographic, laboratory, diagnosis,
and medication data from electronic health records. Each site
received local institutional review board approval to participate
in CNICS and written informed consent was obtained from
patients.
For this analysis, we identified ART-naive individuals initiating
a TFE regimen from July 2003 to October 2012. Patients were
divided into those that began TFE as an STR compared with an
MTR. The outcome was VF that we defined in 2 distinct ways:
first, in base model 1, VF was defined as a single HIV viral load
(VL) >400copies/mL at least 180 days after ART initiation;
second, in the confirmed model 2, VF was defined as the date of
the initial of 2 consecutive VL >400copies/mL at least 14 days
apart, at least 180 days after ART initiation. VL measurements
prior to day 180 were ignored and individuals who died before
180 days excluded. Loss to follow-up was defined as a >210 day
gap in care. Individuals were censored at the time of regimen
change (including MTR to STR), last recorded VL, or date of
last visit if they were lost to follow-up. We fit separate Cox
proportional hazards regression models stratified by clinical site
for each of the 2 VF models and compared persons who initiated
an STRwith those who started anMTR. Hazard ratios (HR) and
95% confidence intervals are reported. Eachwas adjusted for risk
factors associated with VF: race, HIV transmission risk factor,
and baseline CD4 (<200, 200–350, and >350cells/mL) and
continuous log10 HIV VL.
In sensitivity analyses we examined the effect of treatment
period to determine if changes in HIV treatment over calendar
time could account for our results. Among VF patients we
examined the frequency of common resistance mutations:
K103N, M184V/I, K65R, and thymidine analog mutations.3. Results
We observed 2258 patients who began a TFE regimen. Of these,
404 (18%) started an MTR (361 2-pill [89%] and 43 3-pill
[11%]) and 1854 [82%] an STR. At baseline, individuals who
started an STR had higher CD4 counts and lower HIV VL
compared with MTR individuals (Table 1). Among MTR
patients, 245 (61%) began between 2003 and 2005, 122
(30%) in 2006, and 37 (9%) between 2007 and 2012. STRs were
started exclusively after 2005 with 87 (5%) starting in 2006 and
1767 (95%) starting between 2007 and 2012. Using model 1,
137 of 1854 (7%) individuals in the STR arm and 27 of 404 (6%)
individuals in the MTR arm experienced an event. Using the
stricter model 2, 42 of 1854 (2%) in the STR arm and 12 (3%) in
the MTR arm had an event. Patients were censored for regimen
change (45%), last viral load (30%), and lost to follow-up (31%).
In unadjusted analysis, using model 1 the HR of VF was 1.33
[0.87, 2.03] for MTR compared with STR, whereas in model 2
the HR was 1.93[1.00, 3.72]. In adjusted analysis, using model 1
the HR of VF was 1.17[0.76, 1.80], whereas using model 2 the
HR was 1.54[0.78, 3.04] (Supplemental Table 1, http://links.
lww.com/MD/B625). In a sensitivity analysis looking at the effect
of treatment era, the unadjusted hazard of VF in model 1 was
1.60[1.00, 2.56] for the period of 2003 to 2006 and 1.07[0.73,
1.56] for 2007 to 2009 compared with 2010 to 2012.2Among the 164 patients with VF in model 1, we had genotypic
resistance data available for 36 (29 STR, 7 MTR) patients. Of
these, 25 (69%) had a K103N, 4 (11%) a K65R, 14 (39%) an
M184V/I, and 7 (19%) had a thymidine analog mutation. While
a trend was seen toward an increased likelihood of M184V
mutations in the MTR group (5 out of 7) compared with the STR
group (9 out of 29), it did not reach statistical significance. We
found no other significant associations between the frequency of
mutations in individuals on MTR compared with STR regimens.4. Discussion
As the number of individuals treated with ART continues to
increase, many important questions remain about the compara-
tive and cost effectiveness of STR and MTR for the treatment of
HIV infection. A recently published meta-analysis of clinical trial
data showed that lower pill burden was associated with better
adherence and viral suppression[12] in both once-daily and
twice-daily subgroups. The included studies however tended to
compare drugs of different classes which may have impacted
results because of varying drug potency or adherence due to
varying drug side effect profiles. Here, for the first time, we
compared individuals taking the same medications as an STR
with those taking them as an MTR to minimize bias resulting
from variable potency or toxicity profiles of component
medications.
In this analysis, we observed no significant difference in the
development of VF between individuals started on an MTR
compared with an STR TFE regimen though did see a larger
hazard of VF in the MTR group; however, this difference was
imprecise and the numerically higher rate of failure in the STR
arm was likely due to longer duration of exposure in that arm.
The overall number of VF events using either definition of VFwas
low which reduced the precision of our results, but the largest
limitation of our study is that with the release of STR TFE in
2006, nearly all individuals initiating TFE after 2006 started an
STR and those on an MTR nearly all switched to an STR
truncating follow-up. As a result, the population of persons who
started an MTR is heavily weighted to the pre-2007 period and
we cannot exclude the possibility that unmeasured differences
attributable to differing treatment era effects may have impacted
our results.
Our study has a number of other limitations. Like all
observational studies we cannot rule out unmeasured confound-
ing. As CNICS is a cohort of patients seen for routine clinical care
Drozd et al. Medicine (2017) 96:14 www.md-journal.comat US academic medical centers, our findings may not be
applicable in other settings, particularly in resource-limited
settings. We had virologic resistance on only a small subset of
patients who met our VF criteria and did not observe any
significant associations comparing the frequency of specific
resistance mutations between MTR and STR regimens. The
suggestion of more M184V mutations in the MTR group is
however intriguing and deserves further study. In addition
because of the small number of persons with resistance data, it is
possible that individuals may have met our definitions of VF due
to poor adherence either due to pill burden or side effects without
having developed genotypic resistance, though given that the
component medications are the same, we do not believe that side
effects should have varied between groups.
Our study also has a number of important strengths. It was
conducted in a large and well-characterized cohort of HIV-
infected individuals. We assessed 2 distinct definitions of VF
because true clinical VF requires the treating clinician to assess
detectable HIV VL in the setting of his or her assessment of a
patient’s adherence. As a result, no model of VF is perfect, though
we believe that the confirmed model 2 likely represents
individuals with more certain VF.
In summary, we did not find a significant difference in the
development of VF for individuals treated with an STR versus an
MTR TFE regimen, though this result may be confounded by the
different treatment eras in which MTR and STRs were predomi-
nantly prescribed. While many studies have shown improved
adherence and patient satisfaction with STR and ART adherence
remains an important predictor of clinical outcomes in HIV-
infected patients, important questions remain about the relative
effectiveness of STR versus MTR. Future larger analyses should
continue to focus on the development of virologic resistance.Acknowledgments
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